1219956-68-9Relevant academic research and scientific papers
Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode
Meyers, Marvin J.,Pelc, Matthew,Kamtekar, Satwik,Day, Jacqueline,Poda, Gennadiy I.,Hall, Molly K.,Michener, Marshall L.,Reitz, Beverly A.,Mathis, Karl J.,Pierce, Betsy S.,Parikh, Mihir D.,Mischke, Deborah A.,Long, Scott A.,Parlow, John J.,Anderson, David R.,Thorarensen, Atli
scheme or table, p. 1543 - 1547 (2010/06/21)
The work described herein demonstrates the utility of structure-based drug design (SBDD) in shifting the binding mode of an HTS hit from a DFG-in to a DFG-out binding mode resulting in a class of novel potent CSF-1R kinase inhibitors suitable for lead development.
